Effects of SLV329 on Kidney Function in Liver Cirrhosis
Author Information
Author(s): Berthold Hocher, Susi Heiden, Karoline von Websky, Ayman M. Arafat, Jan Rahnenführer, Markus Alter, Philipp Kalk, Dieter Ziegler, Yvan Fischer, Thiemo Pfab
Primary Institution: Institute of Nutritional Science, University of Potsdam
Hypothesis
Does chronic selective adenosine A1 receptor blockade with SLV329 exert diuretic effects without impairing renal function in animals with liver cirrhosis?
Conclusion
Chronic treatment with SLV329 prevented the decrease of creatinine clearance in a rat model of liver cirrhosis.
Supporting Evidence
- SLV329 treatment resulted in a significant increase in diuresis and natriuresis without affecting creatinine clearance.
- Cirrhotic animals treated with SLV329 had a lower mortality rate compared to those treated with furosemide.
- Creatinine clearance in cirrhotic animals treated with SLV329 did not differ significantly from non-cirrhotic groups.
Takeaway
This study tested a new drug called SLV329 to see if it helps rats with liver cirrhosis pee better without hurting their kidneys, and it worked well.
Methodology
Male Wistar rats with thioacetamide-induced liver cirrhosis were treated with SLV329, vehicle, or furosemide for 12 weeks, and various kidney functions were measured.
Potential Biases
Potential bias due to funding from Abbott Products GmbH, which holds the patent for SLV329.
Limitations
Creatinine clearance was used instead of inulin clearance, which may not accurately reflect glomerular filtration rate.
Participant Demographics
Male Wistar rats, aged 250-300 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website